Alembic Pharmaceuticals has said the US health regulator has granted fast track designation to its associate company Rhizen Pharmaceuticals SA’s RP6530 (tenalisib) used in the treatment of cancer.
“The US Food and Drug Administration (USFDA) has granted fast track designation for RP6530 (tenalisib)...for the treatment of patients with relapsed/refractory peripheral T-cell lymphoma (PTCL),” Alembic Pharmaceuticals said in a BSE filing today.
Fast track designation is awarded to drugs that treat a serious condition and fill an unmet medical need, it added.
Shares of Alembic Pharmaceuticals were trading down by 0.07 per cent at Rs 514.35 on the BSE.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.